Back to top
more

Pacira BioSciences (PCRX)

(Real Time Quote from BATS)

$16.53 USD

16.53
230,763

-0.04 (-0.24%)

Updated Nov 4, 2024 03:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.

Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down

by Zacks Equity Research

Pacira (PCRX) receives a Paragraph IV Certification notice letter notifying that eVenus has submitted an ANDA for marketing a generic version of Exparel in the United States.

Pacira (PCRX) Down 1.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.

Pacira (PCRX) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 1.32% and -0.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: Pacira BioSciences (PCRX)

by Zacks Equity Research

Pacira BioSciences (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

How Has PCRX Performed 30 Days Post Earnings

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.

Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.

Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research

Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.

Pacira (PCRX) Q1 Earnings Lag Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of -10.17% and 1.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) PPE sales from its medical business are likely to have maintained the momentum. Also, global recovery trends of its dental business are expected to aid Q1 results.

Is a Beat in the Cards for CVS Health (CVS) in Q1 Earnings?

by Zacks Equity Research

Given the increasing number of walk-in-clinical appointments and patient visits, CVS Health (CVS), which has a huge PBM client base, is expected to have seen a sequential rebound in Q1 revenues.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.

Centene (CNC) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Centene's (CNC) first-quarter results are likely to reflect improving premiums and rise in membership, partly offset by escalating costs.

    What's in Store for Perrigo (PRGO) This Earnings Season?

    by Zacks Equity Research

    Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

    Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients

    by Zacks Equity Research

    The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.

    Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss

    by Zacks Equity Research

    Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.

    Pacira (PCRX) Q4 Earnings Beat Estimates

    by Zacks Equity Research

    Pacira (PCRX) delivered earnings and revenue surprises of 6.10% and -0.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    AMRX or PCRX: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    AMRX vs. PCRX: Which Stock Is the Better Value Option?

    Pacira (PCRX) Gets European Commission Approval for Exparel

    by Zacks Equity Research

    The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.

    Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

    by Zacks Equity Research

    Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.